chrisvoncsefalvay/vaers-outcomes huggingface dataset:
after the first vaccine shot my muscles started aching with general fatigue. this lasted about a day and felt like it came and went very quickly. the injection site was still hard and edematous after about 2 weeks.  After the second vaccine I became slightly achy the same day I got the shot but pre-emptively took ibuprofen, which worked well.  it wasn't until the day after my shot (towards the end of my work day) that I became incredibly fatigued and muscles ached.  Later in the evening I developed a sore throat and slight cough, I did not take my temperature but felt I had a slight temperature increase.  the 2nd and 3rd day post shot I was incredibly fatigued with a slight sore throat.  by 4th day post shot I was feeling back to my normal self.
Patient was vaccinated with her father on Feb. 27, 2021, both represented themselves as educators and claimed to be eligible to receive the Moderna vaccine.  Online registration was completed prior to the vaccination through the state registration portal, which includes a review of the Moderna EUA during the consent phase.  This patient received an  initial vaccination without complications and completed the observation period on site.  There have been no complications or adverse reactions reported to date, however when she attempted to schedule a booster dose we realized she was under the age of 18 - and ineligible under the current Moderna EUA.
symptoms started Saturday, Jan 9th after my vaccine on Friday Jan 8th.  Had terrible fatigue and  terrible headaches, very mild nasal congestion, chills, and a rash on my chest.  On Monday, 1/11/21 I was tested for COVID and positive as I was still not feeling well and lost my taste and smell.  I can?t recall if I lost taste and smell on the 10th or the 11th.  Those first few days I slept most all day and the days run together a little bit.  I think maybe mid week, I started with tinnitus.  About Wednesday, Jan 13th, I started with what looked like chicken pox mostly on my legs and back- these were itchy and fluid filled.   Symptoms were starting to improve on Thursday Jan 21st in regards to my ?pox? as I think it was that day where I did not have any new ones that developed.   My fatigue and headaches started to improve that day or the Friday after as well.   I still  notice some fogginess or  mild memory issues, tinnitus is better but not fully gone, taste and smell are returning, fatigue continues to improve, headaches are intermittent.
paxlovid: Treatment of COVID-19; COVID-19; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 73-year-old male patient received BNT162b2 (BNT162B2), on 04Feb2021 as dose 1, single (Lot number: en5318), in left arm, on 25Feb2021 as dose 2, single (Lot number: en6201), in left arm and on 19Oct2021 as dose 3 (booster), single (Lot number: ff2190), in left arm for covid-19 immunisation. The patient had no relevant medical history. Concomitant medication(s) included: PRAVASTATIN, stop date: 01May2022.  The following information was reported: COVID-19 (medically significant) with onset 03May2022, outcome "unknown"; VACCINATION FAILURE (medically significant) with onset 03May2022, outcome "unknown", described as "paxlovid: Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (03May2022) positive; (08May2022) negative; (09May2022) negative. Therapeutic measures were not taken as a result of vaccination failure, covid-19.  Clinical course: Both my wife and I contacted covid she was positive on May 2, and I was on 03May2022 We both went to urgent care on 5May2022 and received Paxlovid and started symptoms improved and we both tested negative on 08May and 09May respectively. Both of us began a runny nose and chest congestion last night. I retested this am and am testing positive with Covid. She has not retested yet. Am wondering what the next step would be? Simply ride this out or is there some other prescribed treatment?   No follow-up attempts are possible. No further information is expected.
with in a few days her bivatsaral forearm pain returns along with skin paresthesia in arm distar to elbow, patient cant grip hard, experiences shock- like pain & dysesthesia.
Initial report received from a pharmacist on 07-Oct-2013: The patient had received FLUZONE (lot number U4694A and expiration date unknown) IM on 03-Oct-2013. On 04-Oct-2013, the patient reported child had temp as high as 102F with no other symptoms. Patient's medical history includes PCN (penicillin allergy). List of documents held by sender: none.
This is an 85-year-old male, brought in by EMS, for evaluation of generalized fatigue, weakness, worsening since this morning.  Patient received a second Covid vaccine shot yesterday.  Family noticed worsening fatigue, and decreased appetite today which prompted evaluation.  He has congestion, but no productive cough.  No known fevers
PATIENT IS EXPERIENCING RASH AND ITCHING AT THE INJECTION SITE. SHE IS NOT HAVING ANAPHYLAXIS REACTIONS, I RECOMMENDED TO TAKE BENADRYL AND CONTACT HER DR. I HAVE ALSO INFORMED HER DOCTOR ALSO AND WILL FOLLOW UP WITH HER LATER.
enlarged lymph node r axilla, no rash, no face/mouth swelling, afebrile, no swelling of extremity
headache; cough; chills; body ache; Fever; This case was reported by a consumer via call center representative and described the occurrence of headache in a 65-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included COVID-19 VACCINE (received 2 doses on an unknown date) and Shingrix with an associated reaction of pyrexia (received the 1st dose in October/ November 2021 and experienced fever and body ache, refer case- US2021AMR259115). Concurrent medical conditions included cancer. Concomitant products included COVID-19 VACCINE.   On 14th December 2021, the patient received the 2nd dose of Shingrix. On 14th December 2021, 8 hrs after receiving Shingrix, the patient experienced headache, cough, chills, general body pain and fever. Rechallenge with Shingrix was positive. On an unknown date, the outcome of the headache, cough, chills, general body pain and fever were not recovered/not resolved.   It was unknown if the reporter considered the headache, cough, chills, general body pain and fever to be related to Shingrix.  Additional details were provided as follows: The case was self reported by the patient. The patient still had cough and was not sure if it was due to Shingrix or if it was Covid related. The reporter stated that, that the symptoms were still ongoing. The reporter consented to follow up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR259115:same reporter
Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 11-FEB-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 (strength 0.5 mL, lot # L027282, expiration date 21-SEP-2017, dose and route were unknown). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion five times. The total cumulative excursion time (hour), the lowest recorded temperature (Fahrenheit degree) and the type of excursion (R/F) for the first excursion was 16, 33 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree) and the type of excursion (R/F) for the second excursion was 88, 32 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree) and the type of excursion (R/F) for the third excursion was 208, 31 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree) and the type of excursion (R/F) for the fourth excursion was 112, 30 and R. The total cumulative excursion time (hour), the highest recorded temperature (Fahrenheit degree) and the type of excursion (R/F) for the fifth excursion was 72, 29 and R. This is one of several reports received from the same source. Additional information has been requested.
vial was first punctured: 03Oct2022 around 1PM administration of vaccine: 04Oct2022 around Noon/ Dose administered more than 12 hours post puncture; No adverse event; Dose administered more than 12 hours post puncture/Dose administered after exposure to room temperature more than 24 hours; This spontaneous case was reported by a consumer and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered more than 12 hours post puncture/Dose administered after exposure to room temperature more than 24 hours), PRODUCT STORAGE ERROR (vial was first punctured: 03Oct2022 around 1PM administration of vaccine: 04Oct2022 around Noon/ Dose administered more than 12 hours post puncture) and NO ADVERSE EVENT (No adverse event) in an 84-year-old male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7140C) for COVID-19 prophylaxis.     No Medical History information was reported.    On 04-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 04-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered more than 12 hours post puncture/Dose administered after exposure to room temperature more than 24 hours). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vial was first punctured: 03Oct2022 around 1PM administration of vaccine: 04Oct2022 around Noon/ Dose administered more than 12 hours post puncture) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered more than 12 hours post puncture/Dose administered after exposure to room temperature more than 24 hours), PRODUCT STORAGE ERROR (vial was first punctured: 03Oct2022 around 1PM administration of vaccine: 04Oct2022 around Noon/ Dose administered more than 12 hours post puncture) and NO ADVERSE EVENT (No adverse event) outcome was unknown.      Patient age was 84 years 6 months.  No concomitant medication information provided.  Dose administered more than 12 hours post puncture and Dose administered after exposure to room temperature more than 24 hours.  Individual vials or unbroken cartons 1 vial. Vial size was 2.5 mL and was administered around noon. The vial stored post puncture at room temperature. Date and time the vial was first punctured was 03-Oct-2022 around 1PM. Date, the vial was initially stored in the refrigerator was 21-Sep-2022. The vial did not undergo any temperature excursions.  Total amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F) was 23 hours.  No treatment information provided.
Mom said child had redness and area felt hot to the touch (around injection site/shoulder area) Advised to use cool compresse - give TYLENOL for comfort. Bring child in if Sxs increase or Pt did not improve. Mom agreeable
This spontaneous report was received from a healthcare worker refers to an unspecified patients of unknown age. On an unknown date, the patients were vaccinated with an improperly  stored (Oka/Merck) VARIVAX (lot # L005299, expiry date 17-FEB-2017). No adverse effect was reported. This is one of the several reports received from the same reporter. Additional information has been requested.
Patient received his second dose of the Pfizer vaccine.  He was accompanied by his daughter.  Per daughter prior to receiving his vaccine he was his "normal" self.  He was sitting in a chair next to the vaccinator.  He did walk in with a walker and minimal assistance from his daughter.  He did have a gait belt on around his waist.     When I came to patient he was looking straight ahead with his left eye open - right eye s/p surgery to his right eye per daughter.  He did not respond to questions asked.  His daughter stated mentally he is normally intact.  His pulse was faint but palpable.  His color was pale with slight dusky skin to hands.  911 was called.  Undetectable blood pressure initially with his faint pulse. Initially his heart rate was 105.  He was shallow breathing.     BP was undetectable sitting - with oxygenation low 80's on room air.  He was lifted to a bed/cart with legs elevated.  He was given supplemental oxygen.  After laying down with legs up he started to look around.  He was able to tell me his name and respond to questions.     His blood pressure was 117/68 with heart rate 55 and oxygenation on 6L nasal cannula 87-88%.     Patient's daughter stated that patient was recently at hospital with low blood pressure and questionable seizure activity.  No obvious seizure activity noted today.   Parametics - updated with patient history and events.  Blood sugar checked at 183.  Patient neurologically improved with ability to state name, his daughters name and his age.     No injury noted.  Dr phoned and updated on patient condition and events.  Patient transported without injury on oxygen.  Two daughters with patient to emergency room.    Pt being evaluated by cardio on admission for sycope/possible seizure. Still admitted
Weakness, lost appetite, chills, sweats, dizzy, and muscle cramp in my right leg. Lasted from Saturday - Wednesday. Stayed in bed for Sat-Tuesday. My left arm was swollen and red and painful but doctor's office warned me about that not the other.
a hard time following technical more complex conversations; mentally exhausted; some cognitive issues; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 59 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 24Jul2021 17:00 (Lot number: FA7484) at the age of 59 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "A. FIB/ A. Flutter", start date: Apr2021 (unspecified if ongoing), notes: a. fib/a flutter and had an ablation in APR 2021, which was very successful; "COVID-19" (unspecified if ongoing), notes: last year, he did have COVID infection and describes that he had  moderate covid effects and it was fine up until just this last week, he felt pretty fine. The patient's concomitant medications were not reported. The following information was reported: COGNITIVE DISORDER (non-serious) with onset 2021, outcome "unknown", described as "some cognitive issues"; LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES (non-serious) with onset 02Aug2021, outcome "not recovered", described as "a hard time following technical more complex conversations"; MENTAL FATIGUE (non-serious) with onset 02Aug2021, outcome "not recovered", described as "mentally exhausted". The events "some cognitive issues", "a hard time following technical more complex conversations" and "mentally exhausted" were evaluated at the physician office visit.  Additional information: After taking the first dose of vaccine the patient has noticed some cognitive issues. States with his job he does heavy data analysis and methodologies. since having the covid dose, he notices he had several experiences in which he had a hard time following technical more complex conversations before getting mentally exhausted. He was unable to follow certain patterns that he normally does every day. He was in good health with no risk factors. He thought there may be a causal effect with the Covid vaccines that he's had. He states basically it's more of a cognitive issue. He states the injection was good, everything was fine. He still works in the tech industry and the only way he can really describe it is he has to focus so hard that he gets completely exhausted. He states that's the biggest issue he's having. When he's dealing with data and data analysis its like he can't keep track of where it's going, he can't keep track of the conversation, that's what he's dealing with right now.   No follow-up attempts are possible. No further information is expected.
Non productive cough; Runny nose; Generally lethargic; This spontaneous case was reported by a consumer and describes the occurrence of COUGH (Non productive cough), RHINORRHOEA (Runny nose) and LETHARGY (Generally lethargic) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 040A21A and 006M20A) for COVID-19 vaccination.     No Medical History information was reported.   On 12-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 12-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 09-Apr-2021, the patient experienced COUGH (Non productive cough), RHINORRHOEA (Runny nose) and LETHARGY (Generally lethargic). At the time of the report, COUGH (Non productive cough), RHINORRHOEA (Runny nose) and LETHARGY (Generally lethargic) had not resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-Apr-2021, Oxygen saturation: 93% (Borderline) Lower oxygenation readings than normal, 93%. On 28-Apr-2021, SARS-CoV-2 test: other (Negative) COVID test was negative..         No concomitant medications were provided. No treatment medications were taken   This case was linked to MOD-2021-103910 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 25-Jul-2021: No new information was provided.
Patient received 2 vaccines this morning at around 10:22 a.m. (covid & flu).  After receiving the 2nd injection at 10:24, patient started to feel nauseous and lightheaded.  Vaccinator quickly reached out for assistance and patient laid down on the cot with a cool cloth.   Vitals obtained at 10:30  HR 64; BP 97/65 (within normal range per patient); SAT 99% RA; skin color = pale Patient was offered fruit bar and water as she stated maybe she hadn't eaten enough at breakfast.  She has ever felt this way after attempting to watch a medical procedure on a family member.   10:33 patient sitting up, advised she was feeling better.   Repeat B/P 71/43 Patient started to feel lightheaded again and laid back down.   Patient was continuously monitored, at 10:46 vitals returned to patients' normal range of B/P 98/64 ; HR 75; SAT 100% RA for 10+ minutes.  Patient was up and walking around at the clinic and advised she was feeling back to normal.  Patient advised if anything changed to seek medical attention.
AFTER RECEIVING THE VACCINE, SHE STATED THAT HER TONGUE ON NUMB OR TINGLING. ON SITE EMS RESPONDED. SHE RECIEVED 1 DIPHENHYDRAME 25MG WHEN SHE INITALLY TOLD THE NURSE. EMS EVALUATED HER AND GAVE HER A 2ND DIPHENHYDRAMINE 25MG CAPSULE. VITAL ARE BELOW. SHE FELT BETTER AND EMS RELASED HER TO HOME
felt tired; This spontaneous case was reported by a consumer and describes the occurrence of FATIGUE (felt tired) in a 47-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No medical history was provided by the reporter.     On 06-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 06-May-2021, the patient experienced FATIGUE (felt tired). At the time of the report, FATIGUE (felt tired) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
tinnitus; This spontaneous case was reported by a patient family member or friend and describes the occurrence of TINNITUS (tinnitus) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 067h21a, 017b21a and 027a21a) for COVID-19 vaccination.     No Medical History information was reported.   On 15-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 12-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 17-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced TINNITUS (tinnitus). At the time of the report, TINNITUS (tinnitus) outcome was unknown. No concomitant medications was provided. Caller stated it was very unusual to develop tinnitus following vaccination with the Moderna COVID19 vaccine. No treatment medications was provided.
Measles-type rash, especially arms which began on 1/19/01. Was dx'd with Scarlet Fever on 1/12/01. Also, has joint pain, especially in elbows.
hot sensation, rash on legs, skin itchy, nausea, dizziness, weakness & diff breathing;seen by several doctors, including cardiologist;all test negative;had mild exposure while in Mexico;touched a cat but knows cats still alive;
Arm was soar at the vaccine injection and to this day is still.  Getting better, however, should not be taking this long
nausea, vomiting, sensitivity to light, hearing was muffled, a bit of dizzines.  She vomited 3 times. in a span of 30 minutes.
My arm was sore, I ran a slight fever aches and pains, I felt horrible. I had diarrhea continued till now. I could not leave the house. I saw my GI Dr. She put me on Imodium in evening
Patient's daughter reported on Sunday April 11, 2021  that he started getting a rash on the 7th day after the injection, originating from the injection site and spreading to other parts of the body. Patient will be seeking medical attention ASAP.
experienced vomiting after 1st dose; This case was reported by a pharmacist via call center representative and described the occurrence of vomiting in a 73-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Concurrent medical conditions included gluten intolerance.   On 18th January 2019, the patient received the 1st dose of Shingrix. On an unknown date, less than 2 years after receiving Shingrix, the patient experienced vomiting. On an unknown date, the outcome of the vomiting was unknown.   It was unknown if the reporter considered the vomiting to be related to Shingrix.  Additional details were provided as follows: The patient experienced vomiting after 1st dose of Shingrix. The reporter asked if gluten present in Shingrix, as patient had gluten intolerance. The healthcare professional (HCP) unable to provide full details of vaccine. The reporter asked howto proceed over 6 months for 2nd dose of Shingrix. The reporter Did not consent to follow up.
This spontaneous report was received from a physician and refers to an unspecified number of patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical histories provided. On unknown dates, the patients were vaccinated with improperly stored doses of GARDASIL 9 lot # L043214, expiration date 30-AUG-2017; lot # M003659, expiration date 20-SEP-2017; lot # M009116, expiration date 13-JUN-2018 (dose and route of administration were not reported). None of the patients reported adverse effects. Administered doses of vaccine experienced the temperature excursion of 32.4 degrees Fahrenheit for 3 hours 30 minutes. This is one of several reports received from the same reporter. Additional information has been requested.
Started as hives, erythema on right upper arm, itchy as it quickly spread armpit to chest abdomen, neck, back, other arm, groin, thighs. Avoided face?